Comparison of 5-Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer.

ABSTRACT:

Background

The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5-fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.

Methods

We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence-free survival, overall survival, and adverse events were investigated between the two groups.

Results

Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence-free survival and ove

SUBMITTER: Lee TS 

PROVIDER: S-EPMC12400249 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature